NASDAQ$DNTH
Dianthus Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close
Briefing
Dianthus Therapeutics reported Q2 2026 financial results with a widened net loss driven by increased R&D spending on clinical trials.
Dianthus Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $50.2 million or $0.90 per share. Research and development expenses rose to $48.7 million, while general and administrative expenses were $13.6 million. The company maintained a strong cash position of approximately $1.2 billion, providing runway into 2030, alongside progress on multiple clinical programs for claseprubart and other candidates.
- Net loss widened to $50.2 million ($0.90 per share) from $31.6 million ($0.88 per share) in Q2 2025.
- R&D expenses increased to $48.7 million, primarily due to higher clinical costs and headcount for Phase 2/3 development.
- G&A expenses totaled $13.6 million, up from $8.9 million year-over-year due to increased headcount.
- Cash, cash equivalents, and investments stood at ~$1.2 billion as of June 30, 2026, expected to fund operations into 2030.
Headline financials
Revenue & EPS history
Dianthus Therapeutics Inc · Revenue · Quarterly
$760K
Forward guidance
Company expects continued advancement of clinical trials with top-line data readouts in late 2026 and 2028; strong cash position supports operations into 2030.
Tailwinds
- Phase 3 EMERGE trial initiated in gMG with top-line results expected 2H 2028.
- 75% response rate in interim analysis of Phase 3 CAPTIVATE trial in CIDP.
- Phase 2 MoMeNtum trial in MMN exceeded enrollment; top-line results December 2026.
- Phase 1 data for DNTH212 expected by YE 2026.
- $1.2B cash runway into 2030.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
+1.6%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
73%
11 / 15 earnings
Positive
+11.1%
Q2 2019
Best reaction
-6.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +1.1% | -2.9% | -5.8% | |
| Q4 2025 | +9.7% | -1.7% | +15.7% | |
| Q3 2025 | +1.6% | +10.3% | +33.3% | |
| Q2 2025 | -6.1% | -2.4% | +30.0% | |
| Q1 2025 | +2.5% | +0.5% | -7.5% | |
| Q3 2023 | +0.4% | -0.5% | -16.4% | |
| Q2 2023 | +2.5% | -1.2% | -8.6% | |
| Q3 2020 | -0.9% | -1.4% | +11.7% | |
| Q2 2020 | +0.6% | +0.0% | -8.3% | |
| Q1 2020 | +2.7% | -1.3% | +5.4% | |
| Q3 2019 | -2.2% | -13.5% | +21.2% | |
| Q2 2019 | +11.1% | -0.8% | -13.2% | |
| Q1 2019 | +2.7% | +9.9% | -10.7% | |
| Q3 2018 | -3.4% | -24.7% | -14.1% | |
| Q2 2018 | +1.2% | -4.2% | -4.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro